세계의 만성 소양증 시장 : 국가, 지역별 분석 및 예측(2025-2035년)

Global Chronic Pruritus Market, Analysis and Forecast: 2025-2035

Chronic pruritus is a persistent and often severe form of itching that lasts for more than six weeks. It can be a symptom of various underlying medical conditions, including eczema, psoriasis, liver disease, kidney disease, and neurological disorders. Chronic pruritus is more than just an irritation; it can significantly affect a person's quality of life, leading to sleep disturbances, anxiety, and even depression. Unlike temporary itching caused by external factors (like an insect bite), chronic pruritus is often associated with internal causes, making it more challenging to treat. It can occur alongside other symptoms such as redness, swelling, or scarring in the affected areas.

The chronic pruritus market is driven by increasing prevalence of skin disorders and chronic conditions, increasing awareness and diagnosis, and advancement in targeted therapies. Chronic pruritus is often a symptom of underlying conditions like eczema, psoriasis, liver diseases, and chronic kidney disease. As the global population ages and the prevalence of these conditions increases, the demand for effective treatments for chronic pruritus has also grown. For instance, eczema affects more than 31.6 million people in the U.S. alone, according to the American Academy of Dermatology. This demographic shift is driving demand for therapies to manage itching and discomfort associated with these conditions.

Moreover, there is a growing recognition of chronic pruritus as a significant clinical issue. Healthcare professionals are more attuned to its link to various diseases, and patients are increasingly seeking medical attention for persistent itching, especially when it affects quality of life. Advances in diagnostic techniques and greater patient awareness contribute to the rising demand for pruritus treatments.

Although there are multiple treatments available for managing chronic pruritus, the FDA has yet to approve many targeted therapies specifically for pruritus, which can limit treatment options for patients. Despite advances in research, treatments like topical corticosteroids and antihistamines are still commonly used but often fail to address the underlying causes of itching, leading to limited effectiveness for long-term management.

In addition, many of the existing treatments for chronic pruritus, such as corticosteroids and antihistamines, come with side effects like skin thinning, drowsiness, and increased risk of infection, which can impact patient adherence to treatment regimens. Long-term use of systemic medications, particularly in the elderly, can lead to complications, which may deter patients from fully complying with treatment plans. Also, chronic pruritus is often underdiagnosed or misdiagnosed, as it is frequently attributed to other dermatological conditions or simply managed as a symptom rather than a condition in its own right. This limits the market potential for effective therapies, as patients may not seek treatment or receive appropriate care until their condition worsens.

Biologic therapies are becoming increasingly popular for treating chronic pruritus, especially in patients with eczema, psoriasis, and other skin conditions. Moreover, there is a growing focus on the development of targeted drugs that address the specific molecular mechanisms of pruritus. These therapies offer potential for long-term relief with minimal side effects compared to traditional systemic treatments.

Furthermore, with a better understanding of the molecular pathways involved in pruritus, the market is seeing a shift toward precision medicine based on the specific cause of itching. This approach allows for more effective management of chronic pruritus by targeting the underlying condition, such as eczema or liver disease, rather than just masking the symptom.

Competitive strategies within the market include expanding the therapeutic indications of existing drugs, introducing new biologics, and refining formulations of topical treatments.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Chronic Pruritus Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Epidemiological Analysis
• 1.3 Regulatory Landscape
• 1.4 Key Trends
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraint
  • 1.6.4 Market Opportunities

2. Global Chronic Pruritus Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 North America Chronic Pruritus Market, by Country
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
    • 2.2.2.1 Europe Chronic Pruritus Market, by Country
      • 2.2.2.1.1 Germany
      • 2.2.2.1.2 U.K.
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
    • 2.3.2.1 Asia-Pacific Chronic Pruritus Market, by Country
      • 2.3.2.1.1 Japan

3. Chronic Pruritus Market: Competitive Landscape and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments, by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations, and Business Expansions
• 3.2 Company Profiles
  • 3.2.1 Nuogen Pharma
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Sanofi
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 GalaxoSmithKline plc
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers/End-Users
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 Chugai Pharmaceutical
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Top Competitors
    • 3.2.4.4 Target Customers/End-Users
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View
  • 3.2.5 Galderma
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products / Product Portfolio
    • 3.2.5.3 Top Competitors
    • 3.2.5.4 Target Customers/End-Users
    • 3.2.5.5 Key Personnel
    • 3.2.5.6 Analyst View
  • 3.2.6 Mirum Pharmaceuticals
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products / Product Portfolio
    • 3.2.6.3 Top Competitors
    • 3.2.6.4 Target Customers/End-Users
    • 3.2.6.5 Key Personnel
    • 3.2.6.6 Analyst View
  • 3.2.7 Others

4. Research Methodology